DOCSLIB.ORG

Endogenous Prostaglandin E Human and Experimental Duodenal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endogenous Prostaglandin E Human and Experimental Duodenal Endogenous Prostaglandin E2 in Human and Experimental Duodenal Ulceration. By Stirling Pugh MRCP A thesis submitted to University College, London for the degree of Ph. D. in Clinical Science, From The Department of Surgery and Gastroenterology, Rayne Institute, Faculty of Clinical Science, University College, London. ProQuest Number: 10630942 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10630942 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 Abstract The aetiology of human peptic ulcer disease is multifactorial. Its association with anti-prostaglandin drugs has lead to the suggestion that mucosal deficiency of prostaglandins, which are known to be protective to the gastrointestinal tract, may be an aetiological factor. The thesis documents a short history of duodenal ulceration and previous work into its pathogenesis and epidemiology. The history of prostaglandins in the gastrointestinal tract, the phenomena of mucoprotection and the evidence for the protective role of these substances are explored. A method for using endoscopic biopsies to assess the endogenous ability to synthesise prostaglandin E 2 (PGE2 ) is described and validated. Synthesis of iPGE 2 (immunoreactive PGE 2 ) in the upper gastrointestinal tract in control subjects is detailed and the effect of demographic factors explored. Synthesis of iPGE2 in patients with duodenal ulceration is estimated and related to all stages of the disease and to histological and histochemical analyses. The human work suggested a deficiency in iPGE 2 in patients with duodenal ulceration, and the timing of this deficiency in relation to ulcer formation is explored in the cysteamine rat model of duodenal ulceration. 2. Dedication This work is dedicated to my wife Susan, to my parents and to Mike. 3. Table of contents Title page 1 Abstract 2 Dedication 3 Table of contents 4 Index to tables 11 Index to figures 14 Index to photomicrographs 15 Acknowledgements 16 Statement of originality 18 Introduction 19 Hypothesis and plan of research 21 Chapter 1 History, epidemiology, and pathogenesis of duodenal ulceration. 23 Short history of duodenal ulceration 24 Epidemiology of duodenal ulcer 30 Pathogenesis of duodenal ulcer 35 Introduction 35 Abnormalities of acid secretion 37 Abnormalities of pepsin secretion 39 Abnormalities of pylorus function 39 Mucosal protection 41 Mucus and bicarbonate secretion 41 Other protective factors 43 Non-gastrointestinal factors which may contribute to ulcerogenesis 43 Possible infective causes of duodenal ulcer 46 Sum m ary 50 4. Chapter 2 History of PGs, their biochemistry and physiology and the mucosal protection phenomenon. 52 History of PGs 53 Biochemistry of PGs and other eicosanoids 55 Nomenclature 58 Metabolism 59 Dietary deficiency in essential fatty acids 59 Inhibition of PG synthesis 60 Physiological and pharmacological effects of PGs 60 PGE2 in the gastrointestinal tract. 60 Action on muscle 60 Gastrointestinal secretion 61 The physiological roles of PGs in the stomach and duodenum 62 Histamine 2 receptor stimulation and acid secretion 62 Motility 63 Duodenal bicarbonate secretion 64 Eating 64 Permissive action of corticosteroids 64 Diet 65 In summary 66 NSAIDs and peptic ulceration 67 Mucosal protection 71 Introduction 71 History of 'cytoprotection' (mucosal protection). 71 Adaptive mucosal protection 76 Mechanisms of mucosal protection 76 Mucosal bicarbonate secretion 77 Mucus secretion 81 Mucosal blood flow 82 Mucosal cell turnover 85 Preservation of tight junctions 86 In summary 86 Mucosal protection by other substances 86 Carbenoxolone 86 Bismuth compounds 87 Other metal salts 90 5. Sucralfate 90 Other substances 92 Alternative views on mucosal protection and the role of PGs 95 Effect of PGs on isolated cells 98 PGs and mucosal protection in man. 100 Physiological actions 100 Mucosal protection in man 101 Alternative views on mucosal protection and the roles of PGs in man 104 In summary 106 The therapeutic use of PGs and their synthetic analogues 106 Chapter 3 Historical review of the methodology for assessing endogenous PG synthesis 109 Introduction 110 Earliest published method 111 Subsequent attempts 111 Using gastric juice 112 Using venous blood 114 Using mucosal samples 117 PG 'content' of mucosal tissue samples. 117 In vitro synthesis using mucosal tissue samples 119 In vitro synthesis following homogenisation 119 In vitro synthesis in whole mucosal tissue samples 122 In vitro synthesis using vortexed whole tissue samples 126 Chapter 4 Description of method 128 Preparations 129 Obtaining samples 129 H um ans 129 Animals 131 The samples 132 Transfer 132 Weighing 132 6. PG synthesis 133 Radioimmunoassay 134 Potassium phosphate buffer 134 Radioimmunoassay buffer 134 Tritiated PGE 2 135 A ntiserum 135 Standard PGE 2 135 Charcoal mixture 136 Standard curve 136 Validation of the radioimmunoassay 141 Validation of the method of in vitro PG synthesis 142 Chapter 5 Normal values for iPGE 2 in the rat and man 149 Rats 150 Introduction 150 M ethod 150 Results 151 Discussion 154 M an 155 Introduction 155 Subjects and Methods 155 Subjects 155 Biopsies 156 Collection, stratification and statistical analysis of data 156 Results 157 Demography 157 Discussion 166 Chapter 6 In vitro mucosal iPGE 2 synthesis in subjects with duodenal ulcer disease 173 Introduction 174 Methods 174 Subjects 174 Biopsies 175 Treatment 175 Results 176 Demography 176 7. Subjects with duodenal ulcer compared with control subjects 178 Quantitative demographic data of control subjects and the duodenal ulcer sub-groups. 179 In vitro synthesis of 1PGE2 analysed according to biopsy site and clinical group 182 Discussion 185 Early attempts to measure gastroduodenal PGs 189 Plasma PGs in peptic ulcer disease 190 Gastric juice PGs 192 PGs in mucosal samples 194 PG 'content' in mucosal samples 194 In vitro synthesis using mucosal samples 198 Homogenates 198 Culture of mucosal samples 203 Vortex stimulation of mucosal samples 206 In summary 208 Chapter 7 PG synthesis compared to histology and histochemistry 210 Introduction 211 Methods 211 Patients 211 Biopsies 212 iPGE2 synthesis 212 Histology and histochemical examination 212 Statistical analysis 214 Results 215 Histological and histochemical appearances 215 iPGE2 synthesis values 218 Association between histology and iPGE 2 synthesis 222 Discussion 225 Chapter 8 iPGE2 synthesis and histological changes in the cysteamine model of duodenal ulceration in the rat. 229 Introduction 230 M ethods 233 A nim als 233 8. Treatments 234 Experiment design 234 After sacrifice 234 Mucosal samples and IPGE 2 synthesis 235 Histological samples 235 Animal and sample coding 237 Results 237 Postmortem 237 Histology results 238 iPGE2 synthesis 241 Correlation between histological findings and PG synthesis 245 Discussion 248 Chapter 9 Summary and critical review of thesis 256 Summary of thesis 257 iPGE2 synthesis in health and duodenal ulceration 257 Relationship to histological findings 259 Deficiency of mucosal prostaglandins; cause or effect of duodenal ulceration? 260 Importance of the findings in this thesis to the understanding of pathogenesis and healing of duodenal ulceration 261 Therapeutic implications 262 Future research 263 Investigations into the cause of the demonstrated PG deficiency 263 Eicosanoid synthesis in other peptic ulcerative conditions 264 Further clinical studies into the roles of endogenous eicosanoids in duodenal ulcer disease 264 Critical review 265 Measurement of PGE 2 and validation of the assay 266 Patient study design 267 Histological analysis of samples 268 Cysteamine duodenal ulcer model in the rat 269 Hypothesis proved? 274 9. Appendix Table of abbreviations 273 Consent form 274 Patient data entry form 275 Appendices in inside back cover pocket 276 Human raw data - patient demography and iPGE 2 277 Histological data 294 Animal raw data 296 References 297 10. Index to tables Chapter 4 Table 4.1 iPGE2 content of pre- and post-vortex solutions. 144 Table 4.2 Reproducibility and coefficients of variation in duplicate results (pg iPGE 2 mg'1) from control subjects. 145 Table 4.3 Weights (mg) of biopsies from inflamed and non­ inflamed areas pre- and post-freeze drying, and calculated percentage water content. 147 Chapter 5 Table 5.1 Normal iPGE2 values for duodenal samples in female Wistar rats. 152 Table 5.2 Normal iPGE2 values for antral samples in female Wistar rats. 153 Table 5.3 iPGE2 synthesis (pg iPGE2 mg-1) in control subjects. 158 Table 5.4 iPGE2 synthesis (pg iPGE2 mg-1) analysed according to sex. 159 Table 5.5 Duodenal iPGE 2 synthesis (pg iPGE2 mg'1) analysed according to social habits. 159 Table 5.6 iPGE2 (pg iPGE2 mg'1) synthesis analysed according to site of biopsy and age grouping. 160 Table 5.7 iPGE2 (pg iPGE2 mg"1) synthesis analysed according to recruitment centre. 163 Table 5.8 iPGE2 synthesis (pg iPGE2 mg'1) in control subjects from the beginning and end of the study period. 163 Table 5.9 iPGE2 synthesis (pg iPGE2 mg"l) in subjects taking NSAIDs compared to control subjects. 164 Chapter 6 Table 6.1 Patient Groups. 176 Table 6.2 Demographic details of duodenal ulcer subjects. Numbers of subjects in each description within each group. 177 11. Statistical analysis of data in Table 6.2 using y 2 analysis. 178 Quantitative demographic data in control subjects and duodenal ulcer sub-groups. 180 In vitro synthesis of iPGE 2 analysed according to site and clinical group. 183 Statistical analysis of Table 6.5 using Student's t test (two-tailed) for unpaired data. 184 Patient groups 212 Histological and histochemical scoring of biopsies.
Load more

Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2015
    J Gastroenterol DOI 10.1007/s00535-016-1166-4 SPECIAL ARTICLE Evidence-based clinical practice guidelines for peptic ulcer disease 2015 1,2 2 2 2 Kiichi Satoh • Junji Yoshino • Taiji Akamatsu • Toshiyuki Itoh • 2 2 2 2 Mototsugu Kato • Tomoari Kamada • Atsushi Takagi • Toshimi Chiba • 2 2 2 2 Sachiyo Nomura • Yuji Mizokami • Kazunari Murakami • Choitsu Sakamoto • 2 2 2 2 Hideyuki Hiraishi • Masao Ichinose • Naomi Uemura • Hidemi Goto • 2 2 2 2 Takashi Joh • Hiroto Miwa • Kentaro Sugano • Tooru Shimosegawa Received: 25 December 2015 / Accepted: 6 January 2016 Ó Japanese Society of Gastroenterology 2016 Abstract The Japanese Society of Gastroenterology bleeding is first treated by endoscopic hemostasis. If it (JSGE) revised the evidence-based clinical practice fails, surgery or interventional radiology is chosen. Second, guidelines for peptic ulcer disease in 2014 and has created medical therapy is provided. In cases of NSAID-related an English version. The revised guidelines consist of seven ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is items: bleeding gastric and duodenal ulcers, Helicobacter provided. If NSAID use must continue, the ulcer is treated pylori (H. pylori) eradication therapy, non-eradication with a proton pump inhibitor (PPI) or prostaglandin analog. therapy, drug-induced ulcer, non-H. pylori, non-nons- In cases with no NSAID use, H. pylori-positive patients teroidal anti-inflammatory drug (NSAID) ulcer, surgical receive eradication and anti-ulcer therapy. If first-line treatment, and conservative therapy for perforation and eradication therapy fails, second-line therapy is given. In stenosis. Ninety clinical questions (CQs) were developed, cases of non-H.
    [Show full text]
  • Prevalence of Anti-Ulcer Drug Use in a Chinese Cohort
    P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(6):1365-1369 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: [email protected] www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • CLINICAL RESEARCH • Prevalence of anti-ulcer drug use in a Chinese cohort Tzeng-Ji Chen, Li-Fang Chou, Shinn-Jang Hwang Tzeng-Ji Chen, Shinn-Jang Hwang, Department of Family anti-ulcer drugs, e.g. H2-receptor antagonists, synthetic Medicine, Taipei Veterans General Hospital and National Yang-Ming prostaglandins, proton pump inhibitors, and cytoprotective University School of Medicine, Taipei, Taiwan, China agents, has changed the physicians’ treatment patterns in Li-Fang Chou, Department of Public Finance, National Chengchi gastroenterology and greatly improved the ulcer-healing rate University, Taipei, Taiwan, China of patients with peptic ulcer disease[1-6]. In spite of effectiveness Correspondence to: Professor Shinn-Jang Hwang, Department of and popularity, the cost of these drugs has also aroused concern Family Medicine, Taipei Veterans General Hospital, 201, Sec. 2, Shih- [7-11] Pai Road, Taipei 11217, Taiwan, China. [email protected] in the health care systems of developed countries . The concern Telephone: +86-2-28757458 Fax: +86-2-28737901 has been aggravating in recent years because of expanding use of Received: 2003-02-25 Accepted: 2003-03-16 proton pump inhibitors in treating gastroesophageal reflux disease. Although prescribing of these potent acid-suppressing drugs is popular, their patterns of utilization have been infrequently [12-21] Abstract documented in national surveys . In Taiwan area, a single and universal health insurance AIM: To estimate the age-specific prevalence of anti-ulcer program started in 1995 and covered nearly all inhabitants drug use and to calculate the usage of different anti-ulcer (21 653 555 beneficiaries at the end of 2001)[22].
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION O‹cial from June 28, 2019 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. Printed in Japan The Ministry of Health, Labour and Welfare Ministerial Notification No. 49 Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*. NEMOTO Takumi The Minister of Health, Labour and Welfare June 28, 2019 A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*. (The text referred to by the term ``as follows'' are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'' in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmen- tal Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan). Supplementary Provisions (Effective Date) Article 1 This Notification is applied from June 28, 2019. (Transitional measures) Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Pharmacopoeia'') [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No.
    [Show full text]
  • The Prevalence of Endoscopic Gastric Mucosal Damage in Patients with Rheumatoid Arthritis
    RESEARCH ARTICLE The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis Saki Tsujimoto1,2☯, Sho Mokuda1,3☯*, Kenichiro Matoba1, Akihiro Yamada1, Kazuo Jouyama1, Yosuke Murata1, Yoshio Ozaki2, Tomoki Ito2, Shosaku Nomura2, Yasuaki Okuda1 1 Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Ehime, Japan, 2 First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, 3 Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Hiroshima, Japan ☯ These authors contributed equally to this work. * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 a1111111111 Objectives Rheumatoid arthritis (RA) patients often take non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids as supportive drugs. In this study, we investigated the preva- OPEN ACCESS lence of endoscopic gastric damage and their prescribed medications under an actual clini- Citation: Tsujimoto S, Mokuda S, Matoba K, cal condition. Yamada A, Jouyama K, Murata Y, et al. (2018) The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. PLoS ONE 13 Methods (7): e0200023. https://doi.org/10.1371/journal. We collected the data of 1704 RA patients who underwent upper gastrointestinal fiberscopy. pone.0200023 Gastric mucosal erosion and ulcer were classified using modified LANZA score. We ana- Editor: Cristiano Pagnini, Sapienza University of lyzed these data with a multiple regression analysis. Rome, S. Andrea Hopital, ITALY Received: January 24, 2018 Results Accepted: June 17, 2018 The prevalence of endoscopic gastric mucosal damage in these RA patients was 16.7% Published: July 9, 2018 (285 cases). A multiple regression analysis indicated that prednisolone (PSL), NSAIDs Copyright: © 2018 Tsujimoto et al.
    [Show full text]
  • Morphological Study of Gastric Lesions Developing in the Rat Under Several Damaging Conditions: Modifications Induced by Pretreatment with Zinc Acexamate
    Scanning Microscopy Volume 6 Number 3 Article 20 9-9-1992 Morphological Study of Gastric Lesions Developing in the Rat Under Several Damaging Conditions: Modifications Induced by Pretreatment with Zinc Acexamate M. Luisa Bravo Laboratorios Viñas, Barcelona Ginés Escolar Hospital Clínico, Barcelona Carmen Navarro Laboratorios Viñas, Barcelona Ramón Fontarnau Universidad de Barcelona Oriol Bulbena Laboratorios Viñas, Barcelona Follow this and additional works at: https://digitalcommons.usu.edu/microscopy Part of the Biology Commons Recommended Citation Bravo, M. Luisa; Escolar, Ginés; Navarro, Carmen; Fontarnau, Ramón; and Bulbena, Oriol (1992) "Morphological Study of Gastric Lesions Developing in the Rat Under Several Damaging Conditions: Modifications Induced yb Pretreatment with Zinc Acexamate," Scanning Microscopy: Vol. 6 : No. 3 , Article 20. Available at: https://digitalcommons.usu.edu/microscopy/vol6/iss3/20 This Article is brought to you for free and open access by the Western Dairy Center at DigitalCommons@USU. It has been accepted for inclusion in Scanning Microscopy by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. Scanning Microscopy, Vol. 6, No. 3, 1992 (Pages 855-864) 0891- 7035/92$5. 00 +. 00 Scanning Microscopy International, Chicago (AMF O'Hare), IL 60666 USA MORPHOLOGICAL STUDY OF GASTRIC LESIONS DEVELOPING IN THE RAT UNDER SEVERAL DAMAGING CONDITIONS: MODIFICATIONS INDUCED BY PRETREATMENT WITH ZINC ACEXAMATE M. Luisa Bravo, Gines Escolara, Carmen Navarro,
    [Show full text]
  • United States Patent (19) 11) Patent Number: 5,457,128 Yanagawa 45 Date of Patent: Oct
    USOO5457128A United States Patent (19) 11) Patent Number: 5,457,128 Yanagawa 45 Date of Patent: Oct. 10, 1995 54 TOPICAL PREPARATION FOR HEALING Derwent & C.A. 112:84201 Sucralfate-topical. WOUNDS OF THE SKN Baldoni et al. WO/PCT90/02133 (Mar. 8, 1990) Derwent 75 Inventor: Akira Yanagawa, Yokohama, Japan Sucralfate sounds topical/dermal. Caramella et al. EP402933 (Dec. 19, 1990) Derwinet Sucral 73) Assignee: Dott Limited Company, Japan fate Topical. Peterson et al. WO/PCT9104034 (Apr. 4, 1991) Derwent & (21) Appl. No.: 142,468 C.A. 115:42011 Sucralfate Topical Ulcers/Lesions. 22) PCT Filed: Mar. 26, 1993 Fabre FR 2646604 (Nov. 9, 1990) CA.114:129165. 86 PCT No.: PCT/P93/00379 Burch et al. Agents Actions 34(1/2)229-231 (1991) CA. S 371 Date: Nov. 29, 1993 115:174597. Hayashi et al. J. Pediatr. Sug. 26(11):1279–81 Nov. 1991 S 102(e) Date: Nov. 29, 1993 Medline Abstrot. 87). PCT Pub. No.: WO93/19744 Michaeli EP230023 (Jul. 29, 1987) Derwent & C.A. 08:11249. PCT Pub. Date: Oct. 14, 1993 30 Foreign Application Priority Data Primary Examiner–Shep K. Rose Mar. 28, 1992 JP Japan .................................... 4-10862 Attorney, Agent, or Firm-Lorusso & Loud (51 Int. Cl. .................... A61K 31/045; A61 K9/06 57 ABSTRACT 52 U.S. Cl. ............................................. 514/532, 514/546 58 Field of Search ...................................... 514/532, 546 Disclosed is a topical preparation for healing wounds of the skin, which can demonstrate remarkable effects of the treat (56) References Cited ment of wounds of the skin, such as an ulcer of the skin, traumatogenic wounds caused by the abrasion of the skin, U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
    US 2015.0050713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov et al. (43) Pub. Date: Feb. 19, 2015 (54) TECHNOLOGY FOR THE PREPARATION OF Publication Classification MCROPARTICLES (51) Int. Cl. (71) Applicant: Ansun Biopharma, Inc., San Diego, CA CI2N 9/96 (2006.01) (US) CI2N 7/00 (2006.01) CI2N IS/II3 (2006.01) (72) Inventors: Michael P. Malakhov, San Francisco, C07D 305/.4 (2006.01) CA (US); Fang Fang, Rancho Santa Fe, C07K 4/765 (2006.01) CA (US) C07K9/00 (2006.01) (52) U.S. Cl. CPC ................ CI2N 9/96 (2013.01); C07K 14/765 (21) Appl. No.: 14/341,502 (2013.01); C07K9/008 (2013.01): CI2N 15/113 (2013.01); C07D 305/14 (2013.01); (22) Filed: Jul. 25, 2014 CI2N 7/00 (2013.01); C12N 2770/00051 (2013.01) O O USPC ........... 435/188: 530/363; 530/350, 530/367; Related U.S. Application Data 530/385:536/16.8; 536/13.7: 540/336; 530/317; (63) Continuation of application No. 13/874,424, filed on 536/24.5; 530/328; 552/203; 549/510; 435/238 Apr. 30, 2013, now abandoned, which is a continuation (57) ABSTRACT of application No. 13/250,653, filed on Sep. 30, 2011, Mi h duced b tacti lution of a now abandoned, which is a continuation of application 1crospneres are produced by contacting a sol No. 12/179.520, filed on Jul 24, 2008, now aban- macromolecule or small molecule in a solvent with an ant1 doned sa- 1 ws s s Solvent and a counterion, and chilling the solution.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Drug Class Review Proton Pump Inhibitors
    Drug Class Review Proton Pump Inhibitors Preliminary Scan Report December 2014 The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Scan conducted by: Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Pacific Northwest Evidence-based Practice Center Roger Chou, MD, Director Marian McDonagh, PharmD, Associate Director Oregon Health & Science University Copyright © 2014 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. OBJECTIVE The purpose of this preliminary updated literature scan process is to provide the Participating Organizations with a preview of the volume and nature of new research that has emerged subsequent to the previous full review process. Provision of the new research presented in this report is meant to assist with Participating Organizations’ consideration of allocating resources toward a full report update, a single drug addendum, or a summary review. Comprehensive review, quality assessment, and synthesis of evidence from the full publications of the new research presented in this report would follow only under the condition that the Participating Organizations ruled in favor of a full update. The literature search for this report focuses only on new randomized controlled trials, and actions taken by the US Food and Drug Administration (FDA) since the last report. Other important studies could exist.
    [Show full text]